SCHEMBL10134879

SCHEMBL10134879

CCN1CCCC1CNc1nc2cc(-c3nnn[nH]3)ccc2c2ccsc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 5/20 0.38
HSD17B10 Q99714 5/20 0.38
HPGD P15428 4/20 0.38
LMNA P02545 3/20 0.38
POLB P06746 2/20 0.38
DRD2 P14416 1/20 0.38
ACHE P22303 1/20 0.37
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CSNK2A1 P68400 4/20 0.35
PIM1 P11309 2/20 0.35
PIM2 Q9P1W9 1/20 0.35
IRAK4 Q9NWZ3 2/20 0.35
USP2 O75604 1/20 0.34
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
IL1B P01584 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132329 0.93 CSNK2A1 (0.42) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL10132325 0.93 CSNK2A1 (0.42) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL10132276 0.93 CSNK2A1 (0.42) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL10134883 0.88 LMNA (0.40) LMNACSNK2A1
SCHEMBL10134803 0.87 KDM4E (0.39) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL13688024 0.82 KDM4E (0.41) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL10132322 0.81 CSNK2A1 (0.42) LMNACSNK2A1
SCHEMBL10134875 0.79 SLC6A4 (0.40) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL11932401 0.79 KDM4E (0.36) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL13702862 0.79 CSNK2A1 (0.35) CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 KDM4E 736/4885ALDH1A1 3801/4885HSD17B10 4123/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 KDM4E 736/4885ALDH1A1 3801/4885HSD17B10 4123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.